Posted by Michael Wonder on 26 Apr 2022
ObsEva announces confirmation of positive CHMP opinion for linzagolix, an oral GnRH antagonist, for the treatment of uterine fibroids
25 April 2022 - ObsEva today announced that the CHMP of the EMA has confirmed its previously adopted positive opinion, recommending approval of linzagolix for the treatment of uterine fibroids.
The positive CHMP opinion, which was initially adopted on 16 December 2021, was confirmed at the April 2022 CHMP meeting following further review of the linzagolix marketing authorization application.
